Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials

F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
被引用次数：181 相关文章

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

F Petrelli, K Borgonovo, M Cabiddu… - Clinical Lung …, 2012 - clinical-lung-cancer.com
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials.

F Petrelli, K Borgonovo, M Cabiddu… - Clinical Lung …, 2012 - search.ebscohost.com
Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

[引用][C] Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical Lung Cancer, 2012 - cir.nii.ac.jp
Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell
Lung Cancer: A Meta-Analysis of 13 Randomized Trials | CiNii Research CiNii 国立情報学 …

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.

F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical Lung Cancer, 2011 - europepmc.org
Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical Lung Cancer, 2012 - hero.epa.gov
Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials

F Petrelli, K Borgonovo, M Cabiddu… - Clinical lung …, 2012 - pubmed.ncbi.nlm.nih.gov
Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical Lung Cancer, 2012 - infona.pl
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical Lung Cancer, 2012 - infona.pl
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …